Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
<p><strong>Objectives</strong> To examine which composite measures are most sensitive to change when measuring psoriatic arthritis (PsA) disease activity, analyses compared the responsiveness of composite measures used in a 48-week randomized, controlled trial of MTX and etanercep...
Hlavní autoři: | Coates, L, Merola, JF, Mease, PJ, Ogdie, A, Gladman, DD, Strand, V, van Mens, L J.J., Liu, L, Yen, PK, Collier, DH, Kricorian, G, Chung, JB, Helliwell, PS |
---|---|
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
Oxford University Press
2020
|
Podobné jednotky
-
A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combinstion for treating psoriatic arthritis: A comparison of the composite measures used to evaluate disease activity
Autor: Mease, PJ, a další
Vydáno: (2019) -
Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)
Autor: Mease, P, a další
Vydáno: (2018) -
Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination
Autor: Vibeke Strand, a další
Vydáno: (2021-04-01) -
Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
Autor: Helliwell, PS, a další
Vydáno: (2022) -
Methotrexate in psoriasis and psoriatic arthritis
Autor: Coates, L, a další
Vydáno: (2020)